The Corporate Reputation of Pharma Companies, 2017 - The Patient Perspective of 123 Spanish Patient Groups

  • ID: 4593496
  • Report
  • Region: Spain
  • 100 pages
  • PatientView
1 of 5
Spanish Patient Groups Want Closer Relationships with Pharma - But as Equal Partners

FEATURED COMPANIES

  • Abbvie
  • Astrazeneca
  • Bristol-Myers Squibb
  • GSK
  • Merck & Co / Msd
  • Otsuka
  • MORE
  • The views of 123 Spanish patient groups
  • Drawn from a November 2017 - February 2018 survey

Spanish patient groups’ attitudes toward the pharmaceutical industry improved in 2017-though they still remain cautious about pharma, when compared with patient groups from other countries

The Spain-wide findings of the 2017 Corporate-Reputation survey showed that pharma’s corporate reputation significantly increased in that country, 2016 to 2017. 46% of respondent Spanish patient groups stated that the pharma industry as a whole had an “Excellent” or “Good” corporate reputation in 2017, compared with only 28% saying the same in 2016. However, the percentage was even higher in Spain two years before, in 2015-at 48%.

The main drivers for the increase in the industry’s corporate reputation in Spain in 2017 appear to be a more positive attitude that Spanish patient groups are taking to pharma companies’ efforts in the fields of patient centricity, innovation, the provision of high-quality products, corporate integrity, working partnerships with patient groups, and the services that pharma provides ‘beyond the pill’.

However, despite being more favourable toward the pharmaceutical industry in 2017, Spanish patient groups are still not as positive about most of pharma’s activities as patient groups from many other individual parts of the world

What the Spanish patient groups need from pharma

The aims of Spanish patient groups are, for the most part, similar to those of patient groups in other parts of the world. Patient groups everywhere seek to represent the interests of the patients with which they are familiar, and to provide support-with the intention of helping patients lead a better quality of life. Like patient groups elsewhere, Spanish patient groups largely welcome (and, indeed, desire) effective relationships with the pharmaceutical industry. Spanish patient groups’ comments emphasise the need for closer ties with the pharma industry, and greater involvement.

However, comments from Spanish patient groups responding to the 2017 Corporate-Reputation survey make clear that the situation in Spain is complicated by a strict regulatory environment, and by the standards set by the pharma industry’s own Spanish tradesbody, Farmaindustria. These hamper associations between patient groups and industry in Spain-at least, from the perspective of the respondent Spanish patient groups. Some Spanish patient groups call for a campaign to change the regulatory system-particularly, the reframing of Farmaindustria’s rules-to enable closer co-operation between pharma and patient groups.

Spanish patient groups list three types of relationship between themselves and pharma companies:

  1. Arm’s-length relationships. This includes the funding of patient groups by pharma-one of the most common types of relationship between companies and patient groups in Spain.
  2. A closer relationship (but ‘outside the company’). Here, a company might provide any one or more of various forms of non-financial support to the patient groups (or to patients)-such as training, or help in setting up a patient-group campaign or project.
  3. The closest sort of relationship-inside the company’ itself. This relationship sees patients and patient groups become far more involved in a company’s activities, with them offering the company support in becoming more patient centric.

Spanish patient groups seemed to want to shift away from looser forms of relationships with pharma companies, moving, instead, to relationships in which the patient groups act as true partners to the companies, and are treated as equals.

But Spanish patient groups were also adamant that the respective activities of patient organisations and pharma should remain distinct, and that companies should not intrude upon what are specifically patient-group activities. Another caveat is that pharma companies should recognise patient-group needs in any partnership.

So, how did the companies perform at corporate reputation in 2017, in the viewpoints of Spanish patient groups?

Ranking at corporate reputation is measured by patient groups familiar with a company.

  • In 2017, for a third year in a row, Janssen ranked overall 1st for corporate reputation among Spanish patient groups familiar with the company. These patient groups ranked Janssen 1st for four of the 12 individual indicators of corporate reputation (and 2nd at the other eight indicators).
  • Gilead, which was included in the Spanish analysis for the first time in 2017, came next, ranking overall 2nd. Spanish patient groups familiar with the company ranked it 1st for six of the 12 indicators of corporate reputation.
  • Novartis was ranked overall 3rd. Novartis also attained the highest Net Promoter Score (NPS) in this 2017 Spanish analysis: +51.9% (NPS measures patient-group satisfaction with a company).
  • Novo Nordisk (also included for the first time in the Spanish analysis in 2017) ranked overall 4th.
  • Merck & Co/MSD was 5th.
  • AbbVie was 6th.
  • Otsuka was 7th.
  • Merck KGaA was 8th.
  • Eli Lilly was 9th. And...
  • Boehringer Ingelheim was 10th.
  • Merck & Co/MSD made the biggest leap up the corporate-reputation rankings among Spanish patient groups familiar with the company-ranking 5th out of 25 companies in 2017, compared with 10th out of 11 companies in 2016.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abbvie
  • Astrazeneca
  • Bristol-Myers Squibb
  • GSK
  • Merck & Co / Msd
  • Otsuka
  • MORE

Executive Summary
Spanish Patient-Group Relationships With Pharma, 2017
Industry-Wide Findings, 2017
Rankings Of The 25 Pharma Companies, 2017 V. 2016 Among Spanish Patient Groups Familiar With The Companies
Positionings Of 16 Pharma Companies, 2017 V. 2016 Among Spanish Patient Groups That Work/Partner With The Companies
Profiles Of The 25 Companies, 2017

Appendices
I. Spanish Patient Groups: Views On Pharma; And Recommendations For Improvement
Ii. Profiles Of 123 Respondent Spanish Patient Groups, 2017

Tables and Charts
The Pharma Industry’s Corporate Reputation, 2014-2017 (According To Spanish Patient Groups)
How Spanish Patient Groups Would Like Working Relationships With The Pharma Industry To Be, 2017
Companies Ranking 1St For Each Of The 12 Indicators Of Corporate Reputation, 2017(According To Spanish Patient Groups Familiar With The Company)
Number Of Spanish Patient Groups Familiar, And Partnering, With The 25 Companies, 2017
The Types Of Relationships That Spanish Partner Patient Groups Have With Pharmaceutical Companies, 2017
The Corporate Reputation Of The Pharmaceutical Industry, 2017 V. 2016-Compared With That Of Eight Other Healthcare Sectors, According To Spanish Patient Groups
The Pharma Industry’S Corporate Reputation Over Time, 2014-2017 (According To Spanish Patient Groups)
Spanish Patient Groups’ Views On The Efficacy Of The Pharmaceutical Industry At The Indicators Of Corporate Reputation, 2017-Chart And Table
Spanish Patient Groups’ Views On The Efficacy Of The Pharmaceutical Industry At The Indicators Of Corporate Reputation, 2017 V. 2016 V. Patient Groups Worldwide 2017
Spanish Patient Groups’ Views On The Efficacy Of The Pharmaceutical Industry At The Indicators Of Corporate Reputation, 2017, Compared With The Views Of Patient Groups
From 17 Other Countries/Regions, Plus Worldwide-Analysis By Each Indicator  Rankings Of 25 Individual Pharma Companies, 2017 V. 2016 (According To Spanish Patient Groups Familiar With The Company)
Positionings Of 16 Individual Pharma Companies, 2017 V. 2016 (According To Spanish Patient Groups That Work/Partner With The Company)

Charts And Tables For Each Of The 19 Companies:

  • Number Of Spanish Patient Groups Claiming Familiarity With The Company, 2017.
  • Number Of Spanish Patient Groups Saying That They Had A Working Relationship With The Company, 2017.
  • Company Scores Among Spanish Patient Groups Familiar With The Company, And Which Worked With The Company, For Each Of The 12 Indicators Of Corporate Reputation, 2017.
  • Percentage Of The Spanish Patient Groups That Worked With The Company, But Which Also Worked With Other Companies, 2017.
  • Profile Of Respondent Spanish Patient Groups Familiar, And Working, With The Company, 2017: Specialties; Geographic Remit; And Types Of Relationships.
  • The Company PCRIs (Patient Corporate Reputation Index) For Each Of The 12 Indicators - As Assessed By Spanish Companies 2017 V. 2016 V. 2015
  • Overall Rankings For The Company According To Spanish Patient Groups Familiar With The Company, 2017.
  • Overall Positionings For The Company According To Spanish Patient Groups That Work With The Company, 2017.
  • Company Rankings For Each Of The 12 Indicators According To Spanish Patient Groups Familiar, Or Working, With The Company, 2017 V. 2016.
  • The Company’s Net Promoter Score, 2017-As Assessed By Spanish Patient Groups Working With The Company.
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Abbvie
  • Almirall
  • Amgen
  • Astellas Pharma
  • Astrazeneca
  • Bayer
  • Biogen
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Eli Lilly
  • Gilead Sciences
  • Grifols
  • GSK
  • Janssen
  • Leo Pharma
  • Menarini
  • Merck & Co / Msd
  • Merck Kgaa
  • Novartis
  • Novo Nordisk
  • Otsuka
  • Pfizer
  • Roche
  • Sanofi
  • Teva
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll